C12N 2740/16371
Demonstrated in vivo effect
C12N2740/16371 (Demonstrated in vivo effect) appears on 15 US grants and 25 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 25
- Assignees
- 14
- Inventors
- 33
- Latest grant
- 24 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 2 | 1 |
| 2014 | 2 | 2 |
| 2015 | 0 | 2 |
| 2016 | 5 | 4 |
| 2017 | 1 | 3 |
| 2018 | 1 | 1 |
| 2019 | 1 | 0 |
| 2020 | 1 | 2 |
| 2021 | 1 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Therapy for subarachnoid hemorrhage and ischemia24 May 2022US 11,338,015 B2NoNO Inc.
- Pharmaceutical composition for suppressing cell transplant rejection7 Dec 2021US 11,191,808 B2Industry-University Cooperation Foundation Hanyang University
- Cross-reactive T-cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats1 Sep 2020US 10,758,609 B2University of Florida Research Foundation, Inc.
- Therapy for subarachnoid hemorrhage and ischemia28 May 2019US 10,300,110 B2NoNO Inc.
- Cell permeable inhibitors of the scaffold protein plenty of SH3 domains (POSH) or Sh3Rfl27 Feb 2018US 9,901,617 B2The Curators of the University of Missouri
- TDP-43 Interference Peptides, Methods, and Uses Thereof6 Mar 2025US 2025/0073303 A1The University of British Columbia
- Cell-penetrating peptide-microrna conjugates for intracellular cell delivery6 Jul 2023US 2023/0212570 A1North Carolina State University
- Therapy for subarachnoid hemorrhage and ischemia9 Jun 2022US 2022/0175879 A1NoNO Inc.
- Therapy for subarachnoid hemorrhage and ischemia23 Apr 2020US 2020/0121755 A1NoNO Inc.
- Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway27 Feb 2020US 2020/0062805 A1Xigen Inflammation Ltd.
Most cited
By later US patents
- Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen63US 8,454,972 B2GenVec, Inc. · 2013
- Cell-permeable peptide inhibitors of the JNK signal transduction pathway10US 8,748,395 B2Xigen Inflammation Ltd. · 2014
- Therapy for subarachnoid hemorrhage and ischemia6US 9,241,970 B2NoNO Inc. · 2016
- Cell-permeable peptide inhibitors of the JNK signal transduction pathway5US 9,290,538 B2Xigen Inflammation Ltd. · 2016
- Methods and compositions for inhibiting diseases of the central nervous system4US 8,491,890 B2Board of Regents of the University of Nebraska · 2013